Akari Therapeutics, Plc (NASDAQ: AKTX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Akari Therapeutics, Plc (NASDAQ: AKTX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics [Yahoo! Finance]
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity [Yahoo! Finance]
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics